Platinum Investment Management Ltd. Invests $1.86 Million in Boston Scientific Corporation $BSX

Platinum Investment Management Ltd. acquired a new position in shares of Boston Scientific Corporation (NYSE:BSX) in the 4th quarter, Holdings Channel reports. The fund acquired 19,554 shares of the medical equipment provider’s stock, valued at approximately $1,864,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Sumitomo Life Insurance Co. lifted its stake in shares of Boston Scientific by 6.9% during the fourth quarter. Sumitomo Life Insurance Co. now owns 136,372 shares of the medical equipment provider’s stock worth $13,003,000 after buying an additional 8,771 shares during the period. Wealthspire Advisors LLC lifted its stake in shares of Boston Scientific by 134.3% during the fourth quarter. Wealthspire Advisors LLC now owns 13,659 shares of the medical equipment provider’s stock worth $1,302,000 after buying an additional 7,829 shares during the period. Allianz SE lifted its stake in shares of Boston Scientific by 33.4% during the fourth quarter. Allianz SE now owns 18,366 shares of the medical equipment provider’s stock worth $1,751,000 after buying an additional 4,596 shares during the period. Gerber Kawasaki Wealth & Investment Management lifted its stake in shares of Boston Scientific by 4.7% during the fourth quarter. Gerber Kawasaki Wealth & Investment Management now owns 3,082 shares of the medical equipment provider’s stock worth $294,000 after buying an additional 139 shares during the period. Finally, Quadrant Capital Group LLC lifted its stake in shares of Boston Scientific by 0.9% during the fourth quarter. Quadrant Capital Group LLC now owns 32,596 shares of the medical equipment provider’s stock worth $3,108,000 after buying an additional 296 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig bought 3,580 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The stock was bought at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the completion of the transaction, the director directly owned 25,359 shares of the company’s stock, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Cheryl Pegus acquired 1,770 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was purchased at an average cost of $56.49 per share, with a total value of $99,987.30. Following the acquisition, the director directly owned 1,770 shares of the company’s stock, valued at $99,987.30. This represents a ? increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired 9,800 shares of company stock worth $554,012 over the last three months. Company insiders own 0.34% of the company’s stock.

Boston Scientific Trading Down 0.7%

NYSE BSX opened at $46.83 on Friday. The company has a market capitalization of $69.60 billion, a PE ratio of 19.59, a P/E/G ratio of 0.89 and a beta of 0.56. The company has a fifty day moving average of $56.37 and a 200 day moving average of $74.95. Boston Scientific Corporation has a 1 year low of $45.99 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The company had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm’s quarterly revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Research analysts forecast that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific declared that its board has authorized a share repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board believes its shares are undervalued.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analysts remain constructive on Boston Scientific, with one note saying the stock could still rise sharply from current levels despite this year’s de-rating. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
• Positive Sentiment: Boston Scientific may benefit from Penumbra’s newly FDA-cleared stroke thrombectomy platform, which one analyst said could add about $100 million in incremental revenue over time. Penumbra’s FDA nod for clot removal tech a win for Boston Scientific
• Positive Sentiment: BTIG stayed bullish on BSX, pointing to valuation and substantial upside potential despite the recent decline in the share price. BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock
• Positive Sentiment: Boston Scientific reported strong catheter study results, which could support confidence in its clinical pipeline and product adoption. Boston Scientific Corp (BSX) Reports Strong Success Rates From Catheter Study
• Neutral Sentiment: Erste Group trimmed its FY2026 and FY2027 EPS estimates slightly, a modest negative on expectations but not a major change to the broader consensus. Boston Scientific Corporation (NYSE:BSX) – Free Report
• Negative Sentiment: Boston Scientific has repeatedly walked back full-year 2026 guidance, and that ongoing uncertainty is pressuring the stock and contributing to its decline. Meet the Medtech Stock Wall Street Thinks Will Soar 65% Over the Next 12 Months
• Negative Sentiment: One Seeking Alpha piece argues the market is treating BSX like a “broken compounder,” reflecting skepticism that has weighed on the shares. Boston Scientific: The Market Is Pricing A Broken Compounder-We See A Reset One

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Citigroup lowered their price objective on shares of Boston Scientific from $87.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday, May 28th. Mizuho lowered their price objective on shares of Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a research note on Monday, April 13th. Raymond James Financial reiterated an “outperform” rating and set a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a research note on Monday, March 30th. Wells Fargo & Company reiterated an “equal weight” rating and set a $55.00 price objective (down from $75.00) on shares of Boston Scientific in a research note on Thursday, May 28th. Finally, BTIG Research lowered their price objective on shares of Boston Scientific from $80.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, June 2nd. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $85.08.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.